Conventional and Novel Inflammatory Biomarkers in Chronic Heart Failure Patients with Atrial Fibrillation

Gregor Vercek1,2, Borut Jug1,2, Marko Novakovic1,2

  • 1Department of Vascular Diseases, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.

PubMed

Insights

In heart failure patients under 75, higher Interleukin-6 (IL-6) levels and IL-6/Interleukin-10 (IL-10) ratios are linked to atrial fibrillation (AF). This suggests inflammation plays a role in AF development in this population.

Area of Science:

  • Cardiology
  • Immunology
  • Internal Medicine

Background:

  • Atrial fibrillation (AF) is a common arrhythmia linked to poor outcomes in heart failure (HF) patients.
  • Inflammation is implicated in AF, but its specific role in HF patients with AF is unclear.

Purpose of the Study:

  • To investigate the association between inflammatory biomarkers and AF in patients with chronic stable heart failure.
  • To determine if novel inflammatory markers offer additional insight beyond conventional markers.

Main Methods:

  • 111 chronic stable heart failure patients were assessed for conventional (IL-6, hsCRP) and novel inflammatory biomarkers (IL-10, IL-6/IL-10 ratio, orosomucoid, endocan).
  • Biomarker levels were compared based on the patients' cardiac rhythm (AF vs. non-AF).

Main Results:

  • Patients under 75 with AF showed significantly higher IL-6 and IL-6/IL-10 ratio.
  • Elevated IL-6 was a significant predictor of AF in both univariate and multivariate analyses.
  • No significant association was found between other novel inflammatory biomarkers and AF.

Conclusions:

  • IL-6 levels and the IL-6/IL-10 ratio are associated with AF in heart failure patients under 75.
  • Inflammatory molecular signaling, particularly involving IL-6, may contribute to AF development in this patient group.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
68
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
119
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404